Related Experiment Video
Updated: Oct 4, 2025
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Rapid identification of novel independent serum biomarkers in diffuse large B-cell lymphoma
Yi-Qun Che1, Di Wang1, Peng Liu2
1Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background:
Diffuse large B-cell lymphoma (DLBCL) is a common subtype of non-Hodgkin's lymphoma (NHL). We assessed serum biomarkers to identify patients with DLBCL and healthy controls, as well as prognosis-related paired pre- and post-R-CHOP therapy effect of patients with DLBCL.
Methods:
Serum samples from 329 DLBCL patients and 100 healthy controls were collected in this study, as well as 72 samples from additional DLBCL patients with paired pre- and post-R-CHOP therapy (n=36). All serum samples were pretreated and detected by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Serum biomarkers were discriminated between DLBCL patients and healthy controls, as well as between DLBCL patients with prognosis-related paired pre- and post-R-CHOP therapy, and identified by Veristrat Identification Platform 1.0, Bioyong Explore 1.0 and mMass software.
Results:
Two peaks, m/z values of 15,140.74 and 15,885.43, were significantly different from all peaks among the DLBCL patients and healthy controls (P<0.001). Patients with DLBCL could be identified with a sensitivity of 85.9% and specificity of 91.8% of 15,140.74, in the same way for the sensitivity of 92.1% and specificity of 84.4% of 15,885.43. The m/z values of 13,895.80 were downregulated after R-CHOP treatment in DLBCL patients who obtained complete remission (CR) (P=0.018).
Conclusions:
The potential independent serum biomarkers for diagnosis as well as prognosis of DLBCL could be provided for rapid identification.
